Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction.

MLA

Matthew Shane Loop, et al. “Evidence-Based Beta Blocker Use Associated with Lower Heart Failure Readmission and Mortality, but Not All-Cause Readmission, among Medicare Beneficiaries Hospitalized for Heart Failure with Reduced Ejection Fraction.” PLoS ONE, vol. 15, no. 7, Jan. 2020, p. e0233161. EBSCOhost, https://doi.org/10.1371/journal.pone.0233161.

APA

Matthew Shane Loop, Melissa K Van Dyke, Ligong Chen, Todd M Brown, Raegan W Durant, Monika M Safford, & Emily B Levitan. (2020). Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction. PLoS ONE, 15(7), e0233161. https://doi.org/10.1371/journal.pone.0233161

Chicago

Matthew Shane Loop, Melissa K Van Dyke, Ligong Chen, Todd M Brown, Raegan W Durant, Monika M Safford, and Emily B Levitan. 2020. “Evidence-Based Beta Blocker Use Associated with Lower Heart Failure Readmission and Mortality, but Not All-Cause Readmission, among Medicare Beneficiaries Hospitalized for Heart Failure with Reduced Ejection Fraction.” PLoS ONE 15 (7): e0233161. doi:10.1371/journal.pone.0233161.